Chiusura precedente | 50,21 |
Aperto | 50,31 |
Denaro | 50,17 x 700 |
Lettera | 50,42 x 100 |
Min-Max giorno | 48,69 - 52,92 |
Intervallo di 52 settimane | 17,82 - 64,98 |
Volume | |
Media Volume | 487.298 |
Capitalizzazione | 3,158B |
Beta (5 anni mensile) | 1,20 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,73 |
Prossima data utili | 12 mag 2024 - 16 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 71,69 |
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) by over 10 ppt (percentage points)The depth of responses continued to increase fro
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress Peer reviewed data presented during a late-breaking session at the European Academy of Dermatology and Venereology Congress (EADV) confirms the strong profile of sonelokimab in HS announced at MLTX’s R&D Day on June 26, 2023HiSCR75 primary endpoint met with a significantly higher proportion o
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress ZUG, Switzerland, October 4, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that 12-week Phase 2 MIRA trial data for the Nanobody® s